Sinopharm Group Co (1099.HK) Osake Kurssi
Sinopharm Group Co Kurssi
Liikevaihto on kasvanut 18,3 % vuodessa viimeisten 19 vuoden aikana 669,46 Mrd. CNY:een. Osakekohtainen tulos on kasvanut 17,3 % vuodessa viimeisten 19 vuoden aikana. Sinopharm Group Con nettomarginaali on nyt 1,2 %, pääosin vakaa 1,5 %:sta muutama vuosi sitten. Sinopharm Group Con osinkotuotto on tällä hetkellä noin 5,66 %. Jakosuhde on noin 28 % tuloksesta. Osinko on kasvanut 33,1 % vuodessa viimeisten 15 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 20,01 CNY, eli yli nykyhintaa 53,2 %. 23 analyytikosta 16 suosittaa ostoa — kokonaiskonsensus on Osta.
Sinopharm Group Co osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Sinopharm Group Co liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Sinopharm Group Co -osakkeesta
The business model of Sinopharm Group Co Ltd focuses on providing pharmaceutical and healthcare products and services. Sinopharm Group operates through various segments, including Distribution, Retail Pharmacy, Pharmaceutical Manufacturing, and others. As China's largest pharmaceutical distribution and retail company, Sinopharm Group plays a crucial role in the healthcare industry. The company offers a wide range of products, including prescription drugs, over-the-counter medicines, medical devices, and healthcare services. Sinopharm Group aims to enhance the accessibility and affordability of quality healthcare by ensuring the efficient supply chain and expanding its reach across different regions in China.
Sinopharm Group Co Ltd is primarily active in the healthcare industry.
The main competitors of Sinopharm Group Co Ltd in the market are Shanghai Fosun Pharmaceutical Group Co Ltd, China Resources Pharmaceutical Group Ltd, and CSPC Pharmaceutical Group Ltd.
Sinopharm Group Co Ltd, a renowned pharmaceutical and healthcare company, has a rich history and stellar background. Established in 2003, Sinopharm has emerged as a leading player in the healthcare industry. It operates in various segments, including distribution, retail, manufacturing, research, and more. With headquarters in Beijing, China, Sinopharm has focused on expanding its operations globally, establishing a presence across 150 countries. The company strives to improve healthcare accessibility and quality by offering a wide range of products and services, including pharmaceuticals, medical devices, and healthcare solutions. Sinopharm Group Co Ltd's commitment to innovation, quality, and professionalism has earned it a strong reputation in the global market.
Sinopharm Group Co Ltd has achieved several significant milestones throughout its history. One notable accomplishment is the company's successful listing on the Hong Kong stock exchange in 2009, followed by its inclusion in the Hang Seng Index in 2011. Sinopharm has also made significant advancements in the healthcare industry, expanding its portfolio through acquisitions and strategic collaborations. Notably, the company established Sinopharm Holding Guoda Drugstore, an integrated pharmaceutical retailer. In addition, Sinopharm is at the forefront of medical research and development, collaborating with international pharmaceutical companies and contributing to the innovation of new drugs. Sinopharm Group Co Ltd continues to strive for excellence and cement its position as a leading global healthcare company.
Sinopharm Group Co Ltd is primarily present in China.
Sinopharm Group Co Ltd represents the values of integrity, innovation, and excellence. The company is guided by a corporate philosophy that prioritizes customer-centricity and social responsibility. With a focus on healthcare, Sinopharm Group Co Ltd strives to provide high-quality medical products and services to people worldwide. Through continuous research and development, they aim to improve healthcare access and enhance well-being. By upholding its values and corporate philosophy, Sinopharm Group Co Ltd actively contributes to the advancement of the global healthcare industry, making a positive impact on people's lives.
Analyytikot asettavat tällä hetkellä Sinopharm Group Co-osakkeelle keskimääräisen tavoitehinnan 19,39 CNY (mediaani: 20,01 CNY), mikä merkitsee +48,5 % viimeisimpään hintaan verrattuna. Konsensus perustuu 23 analyytikkoarvioon.
23 analyytikkoa arvioi tällä hetkellä Sinopharm Group Co-osaketta: 16 suosittaa ostoa, 7 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Sinopharm Group Co-yhtiöltä 589,72 Mrd. CNY liikevaihtoa ja 2,35 CNY osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Sinopharm Group Co-osake noteerataan hintaan 1,75 EUR (13,06 CNY).
Sinopharm Group Co-osake (1099.HK) on listattuna 5 pörssissä, muun muassa: Hongkong (HKEX) (1099.HK), Frankfurt (X2S.F), München (X2S.MU), Düsseldorf (X2S.DU).
Sinopharm Group Co Ltd is a leading Chinese company specializing in the manufacturing and marketing of pharmaceutical products, medical devices, vaccines, health products, and services. The company covers a wide range of business areas, including the production of medicines, vaccines, medical devices, and medical services. It focuses on customizing its offerings to meet the needs of end customers, establishing itself as a strong player in the global market. The company's main emphasis is on the production and marketing of pharmaceutical products, including a wide range of medicines and medical devices such as eye drops, cough and cold medicines, vitamins and minerals, painkillers, antibiotics, and cancer therapeutics. Sinopharm Group Co Ltd is also a leading provider of vaccines, producing and distributing a broad range of vaccines including those for Hepatitis B, rabies, measles, mumps, and rubella. Additionally, the company offers health products like dietary supplements, diagnostic devices, and medical accessories. It also develops and manufactures medical devices such as urinary catheters, implants, and stents. In addition to these areas, Sinopharm Group Co Ltd is also involved in other segments of the healthcare industry such as hospital management and medical services. It operates a chain of hospitals and pharmacies in China, providing medical services such as consultations, diagnoses, prevention, and rehabilitation. The company's business model is focused on offering products and services tailored to the needs and demands of customers. It invests in research and development to create innovative and cost-effective products and solutions.
odotettu liikevaihto Sinopharm Group Co on 589,72 Mrd. CNY. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Sinopharm Group Co on 7,32 Mrd. CNY. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Sinopharm Group Co:n hinta-voitto-suhde (P/E) on tällä hetkellä 5,57. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Sinopharm Group Co-osakkeen arvostusta.
Sinopharm Group Co:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,07. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Sinopharm Group Co-osakkeen arvostuskennuslukuna.
Sinopharm Group Co:n Eulpool-laatuscore on 6/10.
Sinopharm Group Co:n ISIN on CNE100000FN7. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Sinopharm Group Co:n WKN on A0N99U. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Sinopharm Group Co:n ticker on 1099.HK. Tämä pörssinoteeraus käytetään Sinopharm Group Co-osakkeiden kauppaan pörssissä.
Sinopharm Group Co osake
Sinopharm Group Co vertaisryhmä
Sinopharm Group Co Ticker
Sinopharm Group Co FIGI
Kaikki tunnusluvut ja syvällinen analyysi Sinopharm Group Co:sta
Meidän osakeanalyysimme Sinopharm Group Co-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Sinopharm Group Co:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: